Q122 started slow but ended on a bright note as COVID-19 concerns faded and surgical volumes approached pre-pandemic levels.
Virtually all orthopedic/spine companies experienced the same pattern with elective procedures during the quarter. In general, elective procedure case counts were pressured in January through the beginning of February as a surge in COVID-19 cases impacted patients and contributed to staffing shortages at healthcare facilities. However, by the end of the quarter elective procedures approached or returned to pre-COVID levels.
Among the many topics covered in detail in our comprehensive Q122 OrthoBio Market Recap* are:
- Complete Q122 OrthoBio Market Overview
- SmartTRAK's Expert Analysis and Insights
- All Market News including Revenues, Data, Charts and Shares
- Notable Company-Specific Commentary
- New Product Introductions
- Clinical Trial Activity
- OrthoBio M&A, Deals and Financing
Several companies now report a “backlog” of patients, which along with a generalized recovery in case volumes coinciding with the end of the pandemic, should buoy elective procedures, and in turn biologics revenue, for the next 1-2 quarters. Going forward ...
*The entire unedited article and these links can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below. 
SmartTRAK is a comprehensive, easy-to-use, business intelligence solution for the Life Sciences Industry that provides breaking updates on pertinent company news, potential treatments and guidance, international survey results, statistical analysis by country, studies, trial results, financial impact and more. All subscribers receive a Daily Updates email containing the latest need-to-know news curated by our expert analysts. It's the perfect way to start your day! If you would like to learn more about SmartTRAK, just click here.
